Advanced Melanoma Therapy

The presentation covers advanced therapy options for melanoma, focusing predominantly on immunotherapy. It defines terms such as adjuvant therapy (treatment after primary therapy to prevent recurrence) and neoadjuvant therapy (treatment before surgery). Key points include treatment outcomes from clinical studies involving various checkpoint inhibitors like nivolumab and ipilimumab, demonstrating improved survival rates, particularly when these treatments are combined. Long-term data indicates that patients who responded well at three years remained progression-free significantly longer. The use of targeted therapies compared to immunotherapy for BRAF-mutant melanoma is discussed, showing better survival outcomes for those starting with immunotherapy. New developments in cellular therapies, such as tumor-infiltrating lymphocyte therapy, have shown promising results in objective response rates. The presentation also touches on recent studies regarding adjuvant therapy and neoadjuvant strategies, including personalized mRNA vaccines that have improved recurrence-free survival rates. Furthermore, the potential impact of dietary adjustments on treatment responses is explored, alongside the management of immune-related adverse events, indicating the importance of multidisciplinary care in optimizing patient outcomes.